The Minds Behind Rewind

Portrait of Ian J. Reynolds, PhD

Ian J. Reynolds

Chief Executive Officer

Ian is a leading neuro-pharmacologist with a distinguished 20-year career spanning academia, start-up enterprises in neuroscience drug discovery, and pharmaceutical companies where he led large drug discovery and development teams and global licensing and collaboration initiatives. Ian worked on the discovery and development of novel therapeutics for Parkinson’s disease, amyotrophic lateral sclerosis, Huntington’s disease, multiple sclerosis and age-related macular degeneration.

Prior to joining Rewind Therapeutics, Ian was Vice President and Head of Discovery Research at Teva Pharmaceuticals in Pennsylvania, USA, where he led the delivery of new small molecule drugs for the firm’s speciality medicine pipeline. Previous roles include Senior Director of Discovery Biology at Knopp Biosciences LLC in Pittsburgh, and Senior Director at Merck Research Laboratories (West Chester, PA). Between 1988 and 2005, Ian was at the University of Pittsburgh School of Medicine, where he led teaching and research programs, edited leading journals, and established an internationally recognized research program in neurodegenerative disease. From 2000 and 2005, he was Tenured Professor and Vice Chair of the university’s Department of Pharmacology.

Ian gained his PhD from the Department of Pharmacology and Experimental Therapeutics at Johns Hopkins University, Baltimore, and was a Postdoctoral Fellow at the University of Chicago Department of Pharmacological and Physiological Sciences.

Guillaume Duvey portrait

Guillaume Duvey

Head of Medicinal Chemistry

Guillaume joined Rewind Therapeutics in February 2020 as Head of Medicinal Chemistry and brings over 20 years of experience in early and late-stage small molecule drug discovery in biotech/pharma.

Prior to joining Rewind, he co-founded in 2015 Pragma therapeutics, a biotech company focusing on the development of novel therapeutics for the treatment of stress-related and hearing disorders. As CSO he was in charge of the research and development of Pragma’s portfolio, leading to the nomination of a drug candidate for the treatment of PTSD.

From 2015 to 2018 he was Senior Director of Chemistry at Prexton therapeutics, where he led the CMC efforts for the development of Foliglurax, a novel mGlu4 positive allosteric modulator for the treatment of Parkinson’s disease, acquired by Lundbeck in 2018.

From 2004 to 2013 Guillaume served as Group Leader then as Research Director at Addex therapeutics where he led several preclinical programs, developing in particular novel allosteric modulators for glutamate receptors for various indications. His work led to numerous small molecule clinical candidate nominations for indications like Parkinson’s disease, anxiety, pain, gastroesophageal reflux disease and mood disorders. He notably led the research collaboration with Janssen Pharmaceutica in Belgium and Spain (J&J group), to develop novel mGlu2 allosteric modulators for the treatment of schizophrenia and anxious depression, and which delivered the clinical candidate ADX71149/JNJ40411813 still in clinical development.  During his tenure at Addex he was also responsible for developing strategical scientific partnerships and technological platform integrating modern techniques for identification, characterization and optimization of preclinical molecules for novel targets and new indications.

Prior to Addex, he joined in 2000 the R&D division of Janssen in France where he focused on small molecule drug discovery and advanced several research programs in oncology, virology and CNS disorders.

Guillaume holds a PhD in organic chemistry from University of Rouen (France) and is co-author of more than 25 patents and peer-reviewed articles, as well as a book chapter dedicated to drugs acting on mGlu2 and mGlu5.

Portrait of Christope Van Vaeck

Christophe Van Vaeck

Financial Consultant

Dr. Christophe Van Vaeck joined Rewind Therapeutics in October 2019 as part-time basis as Financial Advisor. He brings almost 20 years of operational and strategic experience from the Life Sciences financial community. Christophe is also CFO of Handl Therapeutics. Before that he managed for 10 years investments and successful exits for both early stage VC and mature PE companies in the biotech, diagnostic, medtech and healthcare service sectors at Gimv. Christophe held board positions at Multiplicom, Spinart, Almaviva Santé and others. During his time at KBC securities, he was actively involved in the successful initial public offerings and subsequent fundraisings of biotech companies such as Galapagos, Devgen, Thrombogenics and Ablynx. Christophe started his career at Bank Degroof in 2001, after obtaining a PhD in Molecular and Cellular Biology at KULeuven, Belgium. Since the end of 2017, Christophe has dedicated himself fully to organize promising Life Sciences companies to be ready for the next phase of their development.